Last reviewed · How we verify
Discontinuation of thiopurines.
Discontinuation of thiopurines involves stopping the use of immunosuppressive purine analogs to assess disease control and reduce long-term toxicity risks.
Discontinuation of thiopurines involves stopping the use of immunosuppressive purine analogs to assess disease control and reduce long-term toxicity risks. Used for Crohn's disease maintenance therapy de-escalation, Ulcerative colitis maintenance therapy de-escalation.
At a glance
| Generic name | Discontinuation of thiopurines. |
|---|---|
| Sponsor | Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Thiopurines (azathioprine, 6-mercaptopurine) are immunosuppressive agents used in inflammatory bowel disease. Their discontinuation is a clinical management strategy to evaluate whether patients can maintain remission without these agents and to mitigate cumulative risks of bone marrow suppression, hepatotoxicity, and malignancy associated with prolonged thiopurine exposure.
Approved indications
- Crohn's disease maintenance therapy de-escalation
- Ulcerative colitis maintenance therapy de-escalation
Common side effects
- Disease relapse or flare
- Loss of remission
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |